Tempest Therapeutics, Inc.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is cu…
Biotechnology
US, South San Francisco [HQ]
Revenue Breakdowns
Segment Analysis Beta
The financial segments are sourced from the SEC' 10-K statement.Revenue By Top Segments
Tempest Therapeutics, Inc. can't present it's sankey chart.
Historical Revenue By Segment
Last 3Y, in million USDTempest Therapeutics, Inc. can't present revenue by segment
Get PRO Today
With PRO you can bypass the blur for the segment revenues of Tempest Therapeutics, Inc..
If you want to see a demo, head over to the financial segments of AAPL